A 34-year-old man with Brugada syndrome (BrS) presented with electrical storm, manifested as multiple appropriate shocks from his implantable cardioverter-defibrillator over a period of 7 hours. He had not tolerated prior treatment with quinidine, and had self-discontinued cilostazol citing persistent palpitations.
INTRODUCTION
Brugada syndrome (BrS) is characterized by the presence of characteristic electrocardiographic (ECG) changes (coved ST-segment elevation C2 mm with a right bundle-branch pattern) in the right-sided precordial leads (leads V 1 through V 3 ), either at baseline, or after administration of a class I (sodium channel blocking) antiarrhythmic drug associated with cardiac arrest or sudden death in the absence of demonstrable structural heart disease [1]. RVOT and LVOT was also created using the EnSite NavX system. Low voltage, complex, fractionated electrograms and late potentials in the RVOT were identified up to 185 ms after the QRS complex on the endocardial surface (Fig. 2) , and up to 246 ms after the QRS complex on the epicardial surface (Fig. 3 ) on 3-D electro-anatomic mapping. These areas were targeted for RF ablation using a 3.5 mm irrigated tip ablation catheter (Thermocool He was discharged on day five post-procedure after being restarted on oral cilostazol 100 mg twice daily as per referring physician preference.
Clinical characteristics include spontaneous or
He was briefly admitted two weeks after the 
DISCUSSION
BrS is an autosomal dominant genetic disorder with incomplete penetrance, but the precise genetic basis of this condition is known in only *30% of the affected individuals [9] . To date, mutations in 19 different genetic loci have been associated with BrS, which either cause loss of function of the sodium channels or the L-type calcium channels, or cause a gain in function of the potassium channels. Mutations in the SCN5A gene account for *15% of BrS patients, leading to either loss of expression or altered function of the a-subunit of the cardiac sodium channel [9] . The majority of symptomatic BrS patients are male, and male gender is associated with a sevenfold higher risk for cardiac arrest in patients with BrS [10] .
Although ICDs are the mainstay for prevention of sudden arrhythmic death in patients with BrS, they do not reduce the frequency of malignant ventricular arrhythmias. Multiple ICD shocks, albeit appropriate, can be psychologically devastating to the patient [11, 12] , may cause acute myocardial injury [13] , myocardial , and isolated diastolic potentials (yellow arrows) in the RVOT epicardium (panel c) which were targeted for ablation. In each panel, the electrograms on the left are before ablation, while the electrograms on the right are after ablation dysfunction due to changes in transmembrane potential [14] , and have pro-arrhythmic effects [15] . Medications such as quinidine may be effective in reducing ventricular arrhythmias in BrS patients, but adverse effects and drug-drug interactions may preclude their long-term use . This is especially true for younger patients, who may need these medications for decades.
Reduction in the inward sodium current (I Na ) in BrS patients accentuates the action potential (AP) phase 1 notch caused by the transient outward potassium current (I to ), resulting in loss of the dome pattern of phase 2 (inhibition of inward calcium current) of the cardiac AP and shortening of the AP duration (Fig. 6) [16] .
Regions with higher I to density (such as the RVOT epicardium) are most susceptible to the loss-of-function I Na channel mutations present in the majority of BrS patients. Studies from canine cardiac preparations suggest that I to currents are more prominent in male hearts compared to females, which may explain the higher prevalence of the BrS phenotype in males [17] . In addition, differential effects of the reduction in I Na in the RVOT epicardium and endocardium result in a voltage gradient between the RVOT endocardium and epicardium. I to density is also higher in some RVOT epicardial sites than others. These perturbations lead to marked transmural and epicardial dispersion of repolarization, which, combined with the conduction delay caused by reduced I Na , leads to phase 2 reentry. These phase 2 reentry circuits lead to development of PVCs with short coupling intervals, which can be triggers for VT/VF in BrS patients [9, 18] (Figs. 7, 8 ).
Reduced I Na in BrS patients may also manifest a prolonged PR interval, as well as a prolonged HV interval and increased QRS [19, 20] . Late potentials as seen on signal-averaged ECG were shown to be an independent predictor of arrhythmic events in a small study of BrS patients [21] , but larger studies exploring this association are lacking.
Ablative techniques for management of BrS patients initially targeted the short coupled PVCs in the RVOT, which may be triggers for the development of VT/VF episodes. Haissaguerre and colleagues [5] reported a series of seven patients (three of whom had BrS) with documented polymorphic VT or VF, who underwent an EP study and mapping to detect focal ectopic ventricular 'triggers' for the VT/VF episodes. Mapping revealed that the earliest electrogram relative to the onset of the ectopic QRS complex was located within the RVOT (two patients) or the right-sided Purkinje system (one patient). Endocardial ablation of these sites resulted in non-inducibility of VT/VF post-ablation, and was associated with reduced recurrence of VT/VF episodes during short-term (mean 7 ± 6 months) follow-up. Isolated reports using this endocardial approach followed in the literature [22] . Unfortunately, a significant We were unable to pursue a focal ablation strategy due to the absence of spontaneous or induced PVCs in the EP lab, which (as noted) is not an uncommon scenario in BrS patients. In There is conflicting data in the literature regarding the utility of cilostazol for the prevention of ventricular arrhythmias in BrS patients [27, 28] . Current guidelines for management of BrS do not include cilostazol as a potential therapy for patients with BrS [2]. Other experts currently give a class IIb recommendation for the use of cilostazol for arrhythmia suppression in BrS patients [29] . Our patient continued to have persistent palpitations during the short duration (two months) of therapy with cilostazol prior to the ablation. Therefore, we believe it is unlikely that this medication alone has provided such sustained control of his in a non-randomized fashion. After follow-up for at least three years, patients in the combined endo-epicardial group had significantly more freedom from ICD therapies or ventricular arrhythmias compared to the endocardial-only group (84.6% versus 52.2%, p = 0.029) [31] . Recent research suggests that there is considerable overlap in clinical phenotype as well as the molecular mechanisms responsible for ventricular tachyarrhythmias among patients with BrS and ARVD/C [32] . Combined endo-epicardial ablation has also been shown, in small studies, to be feasible and safe for treating monomorphic VT refractory to anti-arrhythmic medications in selected patients with hypertrophic cardiomyopathy [33] .
CONCLUSION
We describe the first reported case of combined (epicardial and endocardial) ablation of abnormal, low-voltage, fractionated late potentials within the RVOT (in the absence of spontaneous or induced ventricular ectopic beats on EP study) for the treatment of Brugada storm. Post-ablation, our patient has not had any recurrences of VT/VF over a follow-up period of forty-one months, the longest follow-up duration for any BrS patient treated with ablation reported in the literature.
Although he remains on pharmacotherapy with oral cilostazol following the procedure, it is unlikely that cilostazol alone produced such sustained control of his ventricular arrhythmia. We propose that a combined ablation of late potentials in the RVOT may be a useful approach for management of selected patients with BrS. 
